Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
==== Hot-melt and room temperature ==== In Hot-melt extrusion, the extrusion head heats the food material slightly above the material's melting point. The melted material is then extruded from the head and then solidifies soon thereafter. This allows the material to be easily manipulated into the desired form or model. Foods such as chocolate are used in this technique because of its ability to melt and solidify quickly. Other food materials do not inherently require a heating element in order to be printed. Food materials such as jelly, frosting, puree, and similar food materials with appropriate viscosity can be printed at room temperature without prior melting.
In Indian culture, vegetarianism has been closely connected with the attitude of nonviolence towards animals (called ahimsa in India) for millennia and was promoted by religious groups and philosophers. The Ācārāṅga Sūtra from 5th century BCE advocates Jain-vegetarianism and forbids the monks from walking on grass in order to avoid inflicting pain on them and prevent small insects dwelling inside from getting killed. The ancient Indian work of the Tirukkuṟaḷ, dated before the 5th century CE, explicitly and unambiguously emphasizes shunning meat and non-killing as a common man's virtues. Chapter 26 of the Tirukkural, particularly couplets 251–260, deals exclusively on moral vegetarianism or veganism. Hemachandra, a 12th-century Jain scholar and monk, achieved a significant political victory for vegetarianism in Indian history. He successfully converted King Kumarapala of the Chaulukya dynasty (who ruled present-day Gujarat and surrounding areas) to Jainism. Under Hemachandra's guidance, King Kumarapala issued sweeping imperial edicts (amari-ghoshana) that legally banned the slaughter of animals across his entire kingdom. This alliance is historically responsible for cementing Gujarat as the geographic epicenter of strict vegetarian cuisine in India. In the 16th century, the Jain monk Hiravijaya Suri was invited to the court of the Mughal Emperor Akbar. Through philosophical discussions regarding nonviolence, the monk persuaded the Emperor to issue imperial edicts (farmans) that legally enforced animal welfare across the empire.
Anemia with bone marrow promegaloblastosis (megaloblastic anemia). This is due to the inhibition of DNA synthesis (specifically purines and thymidine). Gastrointestinal symptoms: alteration in bowel motility, such as mild diarrhea or constipation, and loss of bladder or bowel control. These are thought to be due to defective DNA synthesis inhibiting replication in tissue sites with a high turnover of cells. This may also be due to the autoimmune attack on the parietal cells of the stomach in pernicious anemia. There is an association with gastric antral vascular ectasia (which can be referred to as watermelon stomach), and pernicious anemia. Neurological symptoms: sensory or motor deficiencies (absent reflexes, diminished vibration or soft touch sensation) and subacute combined degeneration of the spinal cord. Deficiency symptoms in children include developmental delay, regression, irritability, involuntary movements and hypotonia. Vitamin B12 deficiency is most commonly caused by malabsorption, but can also result from low intake, immune gastritis, low presence of binding proteins, or use of certain medications. Vegans—people who choose to not consume any animal-sourced foods—are at risk because plant-sourced foods do not contain the vitamin in sufficient amounts to prevent vitamin deficiency. Vegetarians—people who consume animal byproducts such as milk and eggs, but not meat or organs—are also at risk.
Sources: en.wikipedia.org
3.D.1 The H+ or Na+-translocating NADH Dehydrogenase ("complex I") family 3.D.2 The Proton-translocating Transhydrogenase (PTH) Family 3.D.3 The Proton-translocating Quinol:Cytochrome c Reductase) Superfamily 3.D.4 Proton-translocating Cytochrome Oxidase (COX) Superfamily 3.D.5 The Na+-translocating NADH:Quinone Dehydrogenase (Na-NDH or NQR) Family 3.D.6 The Putative Ion (H+ or Na+)-translocating NADH:Ferredoxin Oxidoreductase (NFO or RNF) Family 3.D.7 The H2:Heterodisulfide Oxidoreductase (HHO) Family 3.D.8 The Na+- or H+-Pumping Formyl Methanofuran Dehydrogenase (FMF-DH) Family 3.D.9 The H+-translocating F420H2 Dehydrogenase (F420H2DH) Family 3.D.10 The Prokaryotic Succinate Dehydrogenase (SDH) Family
His Imperial and Royal Apostolic Majesty, Francis Joseph I, by the Grace of God Emperor of Austria, King of Germany, King of Hungary, Bohemia, Lombardy–Venetia, Dalmatia, Croatia, Slavonia, Galicia, Lodomeria, Illyria, Serbia, Cumania, Bulgaria, Italy, Rama, Romania, King of Jerusalem, etc. etc.; Archduke of Austria; Grand Duke of Tuscany; Duke of Lorraine, Salzburg, Styria, Carinthia, Carniola and Bukovina; Grand Prince of Transylvania, Margrave of Moravia; Duke of Upper and Lower Silesia, of Modena, Parma, Piacenza and Guastalla, of Auschwitz and Zator, of Teschen, Friaul, Ragusa and Zara and Teck; Princely Count of Habsburg and Tyrol, of Kyburg, Gorizia and Gradisca; Prince of Trento and Brixen; Margrave of Upper and Lower Lusatia, Istria; Count of Hohenems, Feldkirch, Bregenz, Sonnenberg, etc. etc.; Lord of Trieste, of Cattaro and on the Windic March; Grand Voivode of the Voivodeship of Serbia, etc. etc.
== Management == There is no cure for Alzheimer's disease; available treatments offer relatively small symptomatic benefits but remain palliative in nature. Treatments can be divided into pharmaceutical, psychosocial, and caregiving.
== SoBe Beverages == Upon his departure from the NFL, Bello took a position as VP Marketing with Brooklyn, New York-based Ferolito, Vultaggio and Sons, makers of AriZona iced tea. At AriZona he joined a former Pepsi colleague Mike Schott, then COO of AriZona Beverages. After four months he left AriZona to create his own beverage company in partnership with Tom Schwalm that became the South Beach Beverage Company, named after the trendy South Beach area of Miami. The new company, based in Norwalk, Connecticut, marketed so-called "New Age" beverages—exotic juice blends and ready-to-drink iced teas—but faced formidable competition from its predecessors, including Snapple, Mystic, Nantucket Nectars and AriZona. South Beach needed a point of differentiation in the marketplace, so Bello added trace elements of various herbs and nutrients—such as ginseng, ginkgo biloba, guarana, carnitine, Echinacea, yohimbe, taurine and praline—and promoted their benefits beyond hydration. He launched a "3G" line of drinks, which included supposed energy boosters like ginseng, ginkgo biloba and guarana. He also expanded the brand's iced tea portfolio to include more exotic offerings such as Black Tea, Oolong Tea (with bee pollen), Green Tea (with Echinacea) and Red Tea (with selenium).
Sources: en.wikipedia.org
As glucokinase is a monomeric enzyme with only a single binding site for glucose the cooperativity cannot be explained in terms of classical models of equilibrium cooperativity, but requires a kinetic explanation, such as a slow-transition model or a "memonical" model that invokes enzyme memory. The kinetic relationship with the other substrate, MgATP, can be described by classical Michaelis-Menten kinetics, with an affinity at about 0.3–0.4 mM, well below a typical intracellular concentration of 2.5 mM. The fact that there is nearly always an excess of ATP available implies that ATP concentration rarely influences glucokinase activity. The maximum specific activity (kcat) of glucokinase when saturated with both substrates is 62/s. The pH optimum of human glucokinase was identified only recently and is surprisingly high, at pH 8.5–8.7. A "minimal mathematical model" has been devised based on the above kinetic information to predict the beta cell glucose phosphorylation rate (BGPR) of normal ("wild type") glucokinase and the known mutations. The BGPR for wild type glucokinase is about 28% at a glucose concentration of 5 mM, indicating that the enzyme is running at 28% of capacity at the usual threshold glucose for triggering insulin release.
Oxaloacetate to malate, using NADH + H+ Oxaloacetate + NADH/H+ → Malate + NAD+ Fumarate to succinate, catalyzed by an oxidoreductase, Fumarate reductase Fumarate + FADH2 ⇌ Succinate + FAD Succinate to succinyl-CoA, an ATP-dependent step Succinate + ATP + CoA → Succinyl-CoA + ADP + Pi Succinyl-CoA to alpha-ketoglutarate, using one molecule of CO2 Succinyl-CoA + CO2 + Fd(red) → alpha-ketoglutarate + Fd(ox) Alpha-ketoglutarate to isocitrate, using NADPH + H+ and another molecule of CO2 Alpha-ketoglutarate + CO2 + NAD(P)H/H+ → Isocitrate + NAD(P)+ Citrate converted into oxaloacetate and acetyl-CoA, this is an ATP dependent step and the key enzyme is the ATP citrate lyase Citrate + ATP + CoA → Oxaloacetate + Acetyl-CoA + ADP + Pi This pathway is cyclic due to the regeneration of the oxaloacetate. The bacteria Gammaproteobacteria and Riftia pachyptila switch from the Calvin-Benson cycle to the rTCA cycle in response to concentrations of H2S.
A dermal patch or skin patch is a medicated adhesive patch placed on human skin to deliver a medication into the skin. This is in contrast to a transdermal patch, which delivers the medication through the skin and into the bloodstream.
== Structure == Morpholinos are synthetic molecules that are the product of a redesign of natural nucleic acid structure. Usually 25 bases in length, they bind to complementary sequences of RNA or single-stranded DNA by standard nucleic acid base-pairing. In terms of structure, the difference between Morpholinos and DNA is that, while Morpholinos have standard nucleic acid bases, those bases are bound to methylenemorpholine rings linked through phosphorodiamidate groups instead of phosphates. The figure compares the structures of the two strands depicted there, one of RNA and the other of a Morpholino. Replacement of anionic phosphates with the uncharged phosphorodiamidate groups eliminates ionization in the usual physiological pH range, so Morpholinos in organisms or cells are uncharged molecules. The entire backbone of a Morpholino is made from these modified subunits.
The most popular park in the city is Parco del Valentino. In 1961, during the celebrations of Italia61 (Italian unification centenary), an important international exhibition (FLOR61: Flowers of the world in Turin) took place in the park with 800 exhibitors from 19 countries. For the occasion the plan for the new lighting of the park, along with its fountains and paths, was assigned to Guido Chiarelli, the head engineer at the city hall.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.